Key Takeaways MRK faces major headwinds as Keytruda, its top seller, nears the loss of exclusivity in 2028. Gardasil sales dropped 40% in Q1 2025 due to weak China demand, despite strength in other regions. MRK expects IRA's Medicare drug pricing to impact Januvia in 2026 and Keytruda starting in 2028.Merck (MRK) is expected to face several hurdles over the next few years that could affect its long-term growth trajectory, starting with the anticipated loss of exclusivity of its blockbuster PD-L1 inhibitor ...

Key Takeaways PFE expects steady 2025 COVID sales but anticipates major LOE losses and IRA headwinds in the future. Medicare Part D changes may cut into sales of key PFE drugs like Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE trades at 7.82x forward earnings, below industry average, with EPS estimates rising for 2025 and 2026.Pfizer (PFE) is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and ...

面对新冠疫情后持续高企的医疗成本、日益沉重的医保财政压力以及公众对高价药的不满情绪，拜登 政府在原奥巴马时代《平价医疗法案》的基础上，加大力度扩大医保覆盖面，并通过2022年颁布的 《通胀削减法案》首次引入联邦政府与药企直接谈判药品价格的机制。 这些政策举措不仅改变了医药产业的运行环境，也对药企的定价策略与长期创新路径产生深远影响， 成为医药产业投资者高度关注的政策变量。 0 2 0 1 引言 5月18日，美国前总统拜登办公室发布公告称，现年82岁的拜登确诊患有高度侵袭性的前列腺癌，并 已出现骨转移。这一突发消息迅速成为全球舆论焦点，也让人们再次关注这位美国历史上最年长总统 的健康问题。 实际上， 拜登执政期间，医疗健康问题始终是其政府政策的核心关注领域。 拜登政府自2021年执政 以来，在医疗政策领域进行了持续而深入的改革，主要聚焦于医保扩容与药价管控两个方面。 美国医保升级拜登版本 然而，这些改革举措在扩大医保覆盖面的同时，也引发了市场和产业界对成本上升的担忧。尤其是部 分中小企业和中产阶级家庭，由于医保强制参保的相关规定，面临一定程度的经济负担增加。 与此同时，缺乏有效的药品价格控制配套措施，使得专利药 ...

Core Viewpoint - The article discusses the impending "drug price storm" in the U.S. as President Trump announces an executive order to implement a "Most Favored Nation" policy aimed at reducing prescription drug prices by 30% to 80%, targeting the long-standing issue of high drug prices in the U.S. [1][2] Group 1: Policy Announcement - Trump plans to sign an executive order to lower U.S. prescription drug prices, aligning them with the lowest prices in other countries like Canada and Mexico [2][3] - The policy is expected to save the U.S. billions in healthcare costs and reduce the financial burden on citizens [2][3] - This is not the first attempt to address drug prices; a previous "Most Favored Nation" policy was halted by a federal court due to pharmaceutical industry pushback [2][3] Group 2: Current Drug Pricing Landscape - U.S. drug prices are significantly higher than those in other developed countries, with brand-name drugs costing an average of 4.22 times more than in other nations [4][5] - The average price of all drugs in the U.S. is 2.78 times that of 33 other OECD countries [4] - High drug prices are attributed to a lack of government regulation and the ability of pharmaceutical companies to set their own prices [4][5] Group 3: Industry Response - The pharmaceutical industry, represented by the PhRMA, opposes the government's pricing intervention, arguing it would harm patients and increase costs [7] - Industry estimates suggest that the "Most Favored Nation" policy could lead to over $1 trillion in losses for the pharmaceutical sector over the next decade [7] - Trump has criticized the pharmaceutical industry for shifting the burden of research and development costs onto American consumers [7]

Core Viewpoint - Eli Lilly and Company reported mixed first-quarter 2025 results, missing earnings estimates but exceeding revenue expectations, driven by strong sales of its diabetes and weight loss medications [1][2][13]. Financial Performance - Adjusted EPS for Q1 2025 was $3.34, missing the Zacks Consensus Estimate of $3.52, but representing a 29% year-over-year increase [1]. - Total revenues reached $12.73 billion, a 45% increase year-over-year, surpassing the Zacks Consensus Estimate of $12.62 billion [2]. Key Drug Sales - Mounjaro sales were $3.84 billion, up 113% year-over-year, exceeding the Zacks Consensus Estimate of $3.75 billion [3]. - Zepbound generated $2.31 billion in sales, compared to $1.91 billion in the previous quarter, beating the Zacks Consensus Estimate of $2.27 billion [4]. - Trulicity sales fell 25% year-over-year to $1.1 billion, aligning with the Zacks Consensus Estimate [6]. - Jardiance sales increased 48% to $1.01 billion, significantly surpassing the Zacks Consensus Estimate of $675 million [7]. - Taltz generated $761.9 million, up 30% year-over-year, beating the Zacks Consensus Estimate of $663 million [7]. - Verzenio sales were $1.16 billion, a 10% increase year-over-year, but missed the Zacks Consensus Estimate of $1.25 billion [8]. - Emgality revenues dropped 45% to $124.6 million, while Olumiant sales rose 5% to $228.7 million [9]. Guidance and Market Position - The company maintained its 2025 revenue guidance of $58.0 billion to $61.0 billion, indicating a 32% year-over-year growth, but lowered EPS guidance to $20.78 to $22.28 [11][12]. - Competition from Novo Nordisk's semaglutide products is significant, with expectations of strong revenue growth for Novo's offerings [5][16]. - Lilly is investing in obesity treatments and has new molecules in clinical development, including a promising oral GLP-1 agonist [16][18]. Market Reaction - Despite strong sales, Lilly's shares fell nearly 5% in pre-market trading due to the EPS miss and lowered earnings guidance [14]. - CVS Caremark's decision to exclude Zepbound from its preferred drug list may impact sales [14]. - Lilly's stock has increased 16.7% year-to-date, outperforming the industry average of 3.5% [14].